Protocol Ledger

NCT04049097 · Phase III · TERMINATED

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

Interventional Phase III clinical trial protocol NCT04049097 sponsored by ZevraDenmark in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-20 Enrollment: 121 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04049097
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)121 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04049097
Protocol FieldVerified Registry Value
NCT IdentifierNCT04049097
Consolidated Lead SponsorZevraDenmark
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment121 participants (ACTUAL)
Registered Start Date2019-05-20
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI